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e-mail address: eabdelkader@kkkesh.med.sa (E. Abdelkader).Ehab Abdelkader a,b,⇑; Kay P. Yip a,c; Kurt Spiteri Cornish a,dAbstractPurpose: To evaluate the outcomes of pneumatic displacement of submacular hemorrhage secondary to choroidal neovascular
membrane (CNV) (n = 9) and retinal arterial macroaneurysm (RAM) (n = 3).
Methods: This is a retrospective case series study of 12 eyes from 12 patients in Aberdeen Royal Infirmary, Aberdeen, UK. The
mean duration of visual loss was 10.8 ± 4.11 days. All cases received intravitreal injection of expansile gas within 24 h of presen-
tation (C3F8 in 11 cases and SF6 in one case) and postured face down for five days. Anterior chamber paracentesis was done right
after gas injection. Intravitreal anti-VEGF was injected at the same time in cases with CNV. Further anti-VEGF injections were done
in CNV cases as needed afterwards. Cases were followed up for 6 months.
Results: The submacular hemorrhage was successfully displaced from underneath the fovea in all but one case. The bleeding dis-
appeared totally in 44% of cases and was inferiorly displaced in 56%. VA improvement at 6 months was statistically significantly
higher than baseline VA. All cases but 2 (one because of subfoveal fibrosis and one because of late presentation) experienced
improved VA. The mean VA improved from 1.37 ± 0.18 logMAR at baseline to 0.83 ± 0.26 logMAR at 6 months. No complication
related to the procedure was reported.
Conclusion: Pneumatic displacement of submacular hemorrhage appears to be a safe and effective technique to treat the condi-
tion. It is an easy procedure that can be done in outpatient setting. Further studies are needed to validate our results.
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Submacular haemorrhages (SMH) are associated with a
variety of conditions including age-related macular degener-
ation (AMD), retinal artery macroaneuyrsm (RAM), ocular
trauma, pathological myopia and presumed ocular histoplas-
mosis syndrome (POHS).1,2 Retrospective reports of the nat-
ural history of SMH demonstrated poor prognosis. Without
treatment, SMH usually end up with poor final vision.3 This
is due to retinal damage from the haemorrhage itself, whichis toxic to the photoreceptors. The layer of blood also acts as
a diffusion barrier, impairing nutrient diffusion between the
retinal pigment epithelium (RPE) and choroid as well as the
photoreceptors.1 Bennett et al. found that patients with
fovea-involving SMH secondary to AMD had a mean visual
acuity of 20/1700 at final follow-up with observation.4
The intervention for SMH can be done using vitrectomiz-
ing techniques or non-vitrectomizing techniques. Vitrec-
tomizing techniques usually involve doing Pars-Plana
vitrectomy (PPV) with intravitreal or subretinal injection ofe:
al.com
222 E. Abdelkader et al.recombinant tissue-Plasminogen activator (rt-PA) to liquefy
clotted blood and facilitate displacement with gas tampon-
ade. Several case series reported successful displacement
of the SMH (secondary to exudative AMD) and significant
VA improvement with vitrectomizing techniques.5–7 In non-
vitrectomizing techniques intravitreal expansile gases are
injected to displace the SMH from underneath the fovea with
or without other adjuvants. Heriot first described a simple
technique for managing SMH by combined intravitreous
injection of tissue plasminogen activator (t-PA) with expansile
gas to pneumatically displace SMH.8 This technique reported
a high anatomic success rate with few complications. Follow-
ing that, other case series showed favourable outcomes using
intravitreal t-PA in addition to expansile gases to displace
SMH secondary to exudative AMD.9,10 Kitagawa and col-
leagues11 recently published their positive results of using
intravitreal injections of rt-PA, perfluoropropane (C3F8) and
ranibizumab mainly in cases of polypoidal choroidal vascu-
lopathy (PCV). They achieved total displacement of the
SMH in 85% of cases (n = 20) and partial displacement in
15% of cases with significant VA improvement. However,
they had vitreous haemorrhage or retinal detachment in
20% of cases that needed additional surgical intervention.
De Jong and co-workers recently compared the outcomes
of PPV, subretinal rt-PA, C3F8 and bevacizumab to intravit-
real injection of rt-PA, C3F8 and bevacizumab in cases of
SMH secondary to exudative AMD. The authors found no dif-
ference between the 2 groups.12Table 2. Anti-VEGF use in the study.
Patient
no.
Concurrent anti-VEGF
injection
Anti-VEGF
used
Prior anti-VEGF
treatment
1 Yes Ranibizumab No
2 Yes Ranibizumab No
3 No None No
4 Yes Bevacizumab No
5 Yes Ranibizumab Yes
6 Yes Ranibizumab No
7 Yes Ranibizumab No
8 No None No
9 Yes Ranibizumab No
10 Yes Ranibizumab No
11 Yes Bevacizumab Yes
12 No None No
Table 1. Patients’ data, causative pathology, gas used, and VA change.
Patient
no.
Age
(years)
Gender Time from onset of symptoms
to treatment (days)
Cause of
haemorrhage
1 92 M 7 AMD
2 89 F 0 AMD
3 79 F 15 RAM
4 95 F 28 AMD
5 80 F 5 AMD
6 86 F 1 AMD
7 87 F 0 AMD
8 89 F 3 RAM
9 79 F 0 AMD
10 85 F 42 AMD
11 63 M 1 Inflammatory
CNV
12 83 F 28 RAM
M =Male. F = Female. AMD = age-related macular degeneration. RAM = retinal arterial mIn cases of SMH related to RAM, some case series studies
reported successful displacement of the SMH and VA
improvement with PPV + subretinal t-PA injection and gas
tamponade.13,14 However, several complications were
reported with this technique including recurrence of SMH,
vitreous haemorrhage, macular holes, retinal detachment,
and hyphema requiring further interventions to address
them. Some case series studies reported successful displace-
ment of SMH with Intravitreal injection of t-PA and expansile
gas.15 Mizutani et al. reported 100% recurrence of haemor-
rhage following intravitreal injection of t-PA and gas in cases
of SMH secondary to RAM (n = 4) and recurrence of haemor-
rhage in 10% of cases treated with intravitreal gas only
(n = 10). Based on this the authors did not recommend the
use of intravitreal t-PA in SMH secondary to RAM.10
In this retrospective case series study we present the effi-
cacy, safety, and visual outcomes of pneumatic displacement
of SMH in cases of CNV and RAM without the use of rt-PA.
Methods
This study is a retrospective review of 12 consecutive
patients who underwent intravitreal injection of expansile
gas for pneumatic displacement of SMH, from 2009 to
2013 at Aberdeen Royal Infirmary, Scotland, UK. Each patient
had a complete ophthalmological examination at initial pre-
sentation, which included visual acuity (VA), slit lamp biomi-
croscopy, fundus examination and Goldmann applanationNo of injections prior to
haemorrhage
No of injections 6 months post-
haemorrhage
0 6
0 3
0 0
0 2
12 1
0 4
0 3
0 0
0 4
0 3
1 4
0 0
Gas
used
Time to first
FU (weeks)
Visual acuity (logMAR)
Initial
presentation
1st
follow-
up
3
months
6
months
C3F8 4 1.6 0.48 0.3 0.1
C3F8 6 2 0.9 1 0.9
C3F8 4 0.9 0.7 0.6 0.6
C3F8 8 2.3 2.3 2 1.78
C3F8 6 2 2.8 2.8 2.8
C3F8 3 1 0.78 0.48 0.70
C3F8 2 2 2 0.3 0.3
C3F8 6 2 0.7 0.78 0.48
C3F8 5 0.6 0.48 0.4 0.3
C3F8 5 1 0.9 0.6 0.15
SF6 4 0.78 0.6 0.48 0.48
C3F8 4 1.18 1 1 1.18
acroaneurysm. CNV = choroidal neovascular membrane. FU = follow-up.
Figure 1. Colour fundus photographs and OCT images of a case of SMH secondary to RAM successfully treated with intravitreal gas injection. (A) Colour
photograph at presentation. (B) OCT at presentation. (C) Colour photograph at 1 month follow-up. (D) OCT at one month follow-up. (E) Colour
photograph at 6 months. (F) OCT at 6 months.
Submacular haemorrhage 223tonometry. Each patient was consented prior to intravitreal
injection. Where available, fundus fluorescein angiography
(FFA), optical coherence tomography (OCT) and colour fun-
dus photograph (CFP) images pre- and post-procedure were
analysed. All procedures were done in an outpatient setting
with topical anaesthesia. The bulbar conjunctiva was cleaned
and prepared using povidone-iodine to ensure aseptic condi-
tions. 0.3 ml of 100% perfluoropropane gas (C3F8) or sulphur
hexafluoride (SF6) gas was injected intravitreally using a 30
gauge needle 3.5 mm from the limbus in pseudophakic and
4 mm from the limbus in phakic eyes. In cases where
choroidal neovascularisation (CNV) was the cause of the
haemorrhage, ranibizumab or bevacizumab was also injected
intra-vitreally at the same time. Anterior chamber paracente-
sis was done in all cases. Optic disc perfusion was checked
after gas injection in all cases. Intra-ocular pressures were
checked before and after the procedure. Patients were then
advised to maintain face down positioning for five days.
Follow-up data were obtained for all patients at first fol-
low-up (usually around one month), at 3 months and at
6 months after the procedure. Where OCT images were
available, central retinal thickness (CRT) was measured at ini-
tial presentation and follow-up. The area of haemorrhage
and degree of displacement were measured on CFP. VA
obtained using Snellen was converted to logarithm of the
minimum angle of resolution (logMAR) for statistical analysis
Statistical analysis was performed using an IBM SPSS Statis-
tics 22 and Microsoft Excel 2013. Paired Student’s t-testwas used to analyse pre- and post-injection data. A p-value
of less than 0.05 was considered to be significant.
Results
12 eyes of 12 patients (two males and ten females) with
fovea-involving SMH were included in this study. Table 1
summarizes the data that were collected from each patient.
The mean patients’ age was 83.9 ± 2.39 years (range 63–
95 years). The causes of the SMH were neovascular AMD
(n = 8), retinal artery macroaneurysm (n = 3) and inflamma-
tory CNV (n = 1) secondary to serpiginous choroidopathy.
Intravitreal gas injection was performed in all patients by an
experienced medical retina specialist within 24 h of presenta-
tion. All but one patient (patient 10) received 0.3 ml pure per-
fluoropropane (100% C3F8). One case received 0.3 ml pure
sulphur hexafluoride (100% SF6).
The mean duration between onset of symptoms and treat-
ment was 10.8 ± 4.11 days (range 0–42 days). Mean present-
ing visual acuity was 1.37 ± 0.18 (range 0.6–2.3 logMAR). The
time to first follow-up differed among the patients seen and
is dependent on the ophthalmologist who performed the
procedure. Mean time to first follow-up was 4.8 ± 0.46 weeks
(range 2–8 weeks).
Visual acuity improvement was seen in 83.3% (n = 10) of
patients. One of the 2 patients with no VA improvement
was noted to have advanced AMD with subfoveal
fibrosis. Her visual VA was 2.0 logMAR at presentation and
Figure 2. Colour photographs and angiography of a case of SMH secondary to exudative AMD successfully treated with intravitreal C3F8 injection
+ Lucentis injections. (A) Colour photograph at baseline. (B) FFA at baseline. (C) Colour photographs at 3 months follow-up (post gas and 3 lucentis
injections). (D) ICG at 3 months showing a small residual hyperfluorescent spot due to RAP lesion (arrow). (E) Colour photograph at 6 months showing
complete resolution of the lesion. (F) ICG at 6 months showing no residual hyperfluorescence.
224 E. Abdelkader et al.2.8 logMAR at 6 months follow-up. No further treatment was
recommended for that eye because of the irreversible foveal
structural damage. The other case with no VA improvement
presented with a prolonged history of blurred vision (over
4 weeks) and a very thick SMH and central macular thickness
of 1148 lm on OCT. Her VA in the affected eye 1.18 logMAR
at presentation and remained the same at 6 months follow-
up with partial inferior displacement of SMH.Mean visual acuity at first follow-up, at 3 months and at
6 months post-injection was 1.14 ± 0.22 logMAR,
0.92 ± 0.25 logMAR and 0.83 ± 0.26 logMAR respectively.
When compared to visual acuity at initial presentation, the
improvement at first follow-up was not statistically significant
(p = 0.14). However, vision continued to improve and was
statistically significant at 3 months (p = 0.02) and at 6 months
post-injection (p = 0.02).
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intravitreal injections of anti-vascular endothelial growth fac-
tors (anti-VEGF) at the same time as pneumatic injection.
Two of the patients had previous anti-VEGF injections for
prior CNV. Further details of the anti-VEGF therapy are
shown in Table 2. 75% (n = 9) of patients had CFP taken
at initial presentation. In this group of patients, mean haem-
orrhage area before pneumatic displacement was measured
at 20.42 ± 7.29 mm2 (range 3.9–75.1 mm2). The haemor-
rhage completely resolved in 44% (n = 4) and inferior dis-
placement of the haemorrhage with foveal clearing were
achieved in the remaining 56% of patients at 3 months fol-
low-up (n = 5). Initial OCT images were obtained for 50%
(n = 6) of patients. Mean CRT at presentation was
573 ± 128 lm (range 221–1148 lm). At 6 months post-
injection, mean CRT was 196 ± 23 lm (range 110–299 lm).
This was found to be statistically significant (p < 0.01, Stu-
dent’s T-test). Fig. 1 shows pre and post injection appear-
ance of one of our RAM cases. Fig. 2 shows the results of
our technique in a case of SMH secondary to retinal
angiomatous proliferation (RAP). In the later case (pre-
sented in Fig. 2) vision improved from CF at baseline to
6/7.5 at last follow-up.
There were no complications reported immediately post-
surgery or during follow-up in any of the patients included
in this study.Discussion
SMH is associated with poor visual prognosis due to sev-
eral different mechanisms including direct toxicity from the
haemorrhage, mechanical traction on the photoreceptors
and the establishment of a barrier effect between the pho-
toreceptors and retinal pigment epithelium (RPE). Toxicity
from the haemorrhage is caused by iron, in the form of fer-
ritin, which is produced during hemolysis of the bleeding.
Iron toxicity induces destruction of the photoreceptor and
RPE layers. The traction effect on the photoreceptors is due
to fibrin strands which forms within the haemorrhage during
the clot retraction process. The layer of blood present also
acts as a diffusion barrier preventing effective interchange
of nutrients and metabolic by-products between the choroi-
dal circulation and the retina. These three different mecha-
nisms are time-specific and thus contribute to worsening
visual prognosis with increasing duration of SMH.1 Thus, dis-
placement of the haemorrhage is recommended as soon as
possible to reduce damage to the macular photoreceptors
and improve the visual outcome.
In our retrospective study, we demonstrate successful dis-
placement of SMH and significant improvement in vision with
intravitreal injection of expansile gas. Anti-VEGF injection
was also injected in cases of exudative AMD. The technique
is a minimally invasive procedure that can be performed with-
out delay in an outpatient setting where a clean intravitreal
injection room is available. It seems to be a safe procedure
with no complications detected in any of our patients. It is
also a very cost-effective procedure. The potential complica-
tions that could happen with pneumatic displacement of
SMH are similar to any intravitreal injection. No high IOP
was detected in any of our cases post injection but this
required paracentesis to be performed in all cases after gas
injection.Vitrectomizing techniques for SMH involve PPV, which is
an expensive and time-consuming procedure that usually
requires admission to hospital. PPV also needs to be done
in operating theatre with special equipment as well as physi-
cian and nursing expertise. Moreover, PPV is associated with
complications including cataract progression. In addition, vit-
rectomized eyes have short half-life of anti-VEGF drugs that
are usually needed for further management in exudative
AMD cases.16
Non-vitrectomizing techniques with intravitreal t-PA and
gas injection are outpatient-based and simpler compared
to PPV procedures. However, t-PA can cause adverse effects.
Vitreous haemorrhage and rebleeding have been docu-
mented following the intravitreal use of t-PA in SMH
cases.10,17 Hesse et al.18 also reported the occurrence of an
inferior exudative retinal detachments in all patients injected
with high doses of tPA (100 lg) which resorbed sponta-
neously after two weeks. Furthermore, experimental studies
on animal eyes showed retinal toxicity of intravitreal t-PA
injection.19,20
Pneumatic displacement of SMH seems to be an easy an
effective way of treatment of this devastating condition. Its
success depends on many factors including the duration of
bleeding (the shorter the duration, the better the results),
level of haemorrhage (high success in subretinal haemor-
rhage rather than deeper bleedings), and patient compliance
to posture face down for a few days.
Limitations of our study include its retrospective nature,
and hence the absence of fixed protocols for imaging and fol-
low-up of cases. There were also a small number of cases
included in the study.
In conclusion, pneumatic displacement of SMH offers a
safe and effective treatment option of SMH. It is a simple
technique that can be delivered in outpatient clinic settings.
Further studies are needed to validate the efficacy of this
technique and compare its efficacy and cost-effectiveness
with other techniques such as vitrectomy.
Conflict of interest
The authors declare that there are no conflict of interests.
References
1. Hochman MA, Seery CM, Zarbin MA. Pathophysiology
and management of subretinal hemorrhage. Surv Ophthalmol
1997;42(3):195–213.
2. Berrocal MH, Lewis ML, Flynn Jr HW. Variations in the clinical course
of submacularhemorrhage. Am J Ophthalmol 1996;122(6):486–93.
3. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of
macular subretinal hemorrhage in age-related macular degeneration.
Ophthalmologica 1999;213(2):97–102.
4. Bennet SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of
visual outcome in patients with subretinal hemorrhage. Am J
Ophthalmol 1990;109(1):33–7.
5. Kimura S, Morizane Y, Hosokawa M, et al. Submacular hemorrhage in
polypoidal choroidal vasculopathy treated by vitrectomy and
subretinal tissue plasminogen activator. Am J Ophthalmol
2015;159:683–9.
6. Kadonosono K, Arakawa A, Yamane S, et al. Displacement of
submacular hemorrhages in age-related macular degeneration with
subretinal tissue plasminogen activator and air. Ophthalmology
2015;122:123–8.
7. Chang W, Garg SJ, Maturi R, et al. Management of thick submacular
hemorrhage with subretinal tissue plasminogen activator and
pneumatic displacement for age-related macular degeneration. Am
J Ophthalmol 2014;157:1250–7.
226 E. Abdelkader et al.8. Heriot WJ. Further experience in management of
submacularhemorrhage with intravitreal TPA. In: Program and
Abstracts of Vitreoretinal Update 1997; October 24–25, 1997; San
Francisco, p. 82–4.
9. Hattenbach LO, Klais C, Koch FH, Gümbel HO. Intravitreous injection
of tissue plasminogen activator and gas in the treatment of
submacular hemorrhage under various conditions. Ophthalmology
2001;108:1485–92.
10. Mizutani T, Yasukawa T, Ito Y, et al. Pneumatic displacement of
submacular hemorrhage with or without tissue plasminogen
activator. Graefes Arch ClinExpOphthalmol 2011;249:1153–7.
11. Kitagawa Y, Shimada H, Mori R, et al. Intravitreal tissue plasminogen
activator, Ranibisumab, and Gas injection for submacular
haemorrhage in polypoidal choroidal vasculopathy. Ophthalmology
2016, epub ahead of print :1–9.
12. De Jong JH, Van Zeeburg EJ, Cereda MG, et al. Intravitreal versus
subretinal administration of recombinant tissue plasminogen
activator combined with gas for acute submacular hemorrhage due
to age-related macular degeneration: An Exploratory Prospective
Study. Retina 2016, epub ahead of print.
13. Inoue M, Shiraga F, Shirakata Y, et al. Subretinal injection of tissue
plasminogen activator for macular hemorrhage associated with
ruptured retinal arterial macroaneurysm. Graefes Arch
ClinExpOphthalmol 2015;253:1663–9.14. Zeeburg E, Cereda M, Meurs J. Recombinant tissue plasminogen
activator, vitrectomy, and gas for recent submacular hemorrhage
displacement due to retinal macroaneurysm. Graefes Arch
ClinExpOphthalmol 2013;251:733–40.
15. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of
submacularhemorrhage with intravitreous tissue plasminogen
activator injection and pneumatic displacement. Ophthalmology
1999;106(10):1900–7.
16. Ahn SJ, Ahn J, Park S, et al. Intraocular pharmacokinetics of
ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest
Ophthalmol Vis Sci 2014;55:567–73.
17. Kokame GT. Vitreous hemorrhage after intravitreal tissue
plasminogen activator (t-PA) and pneumatic displacement of
submacularhemorrhage. Am J Ophthalmol 2000;129(4):546–7.
18. Hesse L, Schmidt J, Kroll P. Management of acute
submacularhemorrhage using recombinant tissue
plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol
1999;237(4):273–7.
19. Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN.
Retinal toxicity of recombinant tissue plasminogen activator in the
rabbit. Arch Ophthalmol 1990;108(2):259–63.
20. Hrach CJ, Johnson MW, Hassan AS, et al. Retinal toxicity of
commercial intravitreal tissue plasminogen activator solution in cat
eyes. Arch Ophthalmol 2000;118(5):659–63.
